Toxoplasma gondii infection of fibroblasts causes the production of exosome-like vesicles containing a unique array of mRNA and miRNA transcripts compared to serum starvation

Samuel M. Pope¹* and Cecilia Lässer²

¹Department of Biomedical Sciences, Marian University College of Osteopathic Medicine, Indianapolis IN, USA; ²Department of Internal Medicine and Clinical Nutrition, Krefting Research Centre, University of Gothenburg, Gothenburg, Sweden

Background: Until recently thought to be of little significance unless occurring during pregnancy, Toxoplasma gondii infection of human hosts is now known to play a larger role in mental health and is a growing concern in the health care community. We sought to elucidate a possible mechanism by which Toxoplasma infection may cause some of the behavioural pathology now associated with infection. We hypothesized that exosomes may be playing a role.

Methods: We utilized electron microscopy to detect the presence and size of extracellular vesicles in the supernatants of Toxoplasma-infected human foreskin fibroblasts (HFF). We then utilized microarray analysis to discern mRNA and miRNA content of the vesicles isolated from supernatants of Toxoplasma-infected (Toxo) and serum-starved (SS) HFF.

Results: We recovered extracellular vesicles with a size consistent with exosomes that we called exosome-like vesicles (ELVs) from the supernatants of SS and Toxo cultures. The mRNA and miRNA content of these ELVs was highly regulated creating specific and unique expression profiles comparing Toxo ELVs, SS ELVs and RNA isolated from whole cell homogenates. Interestingly, among the most enriched mRNA isolated from ELVs of Toxo cells are 4 specific mRNA species that have been described in the literature as having neurologic activity: Rab-13, eukaryotic translation elongation factor 1 alpha 1, thymosin beta 4 and LLP homolog. In addition, miRNA species uniquely expressed in Toxo ELVs include miR-23b, a well-known regulator of IL-17.

Conclusion: While the production of ELVs containing mRNAs that modify behaviour are consistent with reported Toxoplasma pathology, the mechanism of enrichment and ultimate in vivo effect of these mRNA and miRNA containing ELVs remains to be investigated.

Keywords: Toxoplasma; mRNA; miRNA; exosomes; extracellular vesicles; microarray

To access the supplementary material to this article, please see Supplementary files under Article Tools online.

Received: 29 July 2013; Revised: 30 September 2013; Accepted: 11 October 2013; Published: 11 December 2013
multiples via binary fission before entering a metabolically inactive state, bradyzoite, in a cyst-like lesion. This tropism for neurologic tissue is considered by some to be the cause of well-described Toxoplasma-induced behavioural effects in secondary hosts. The cause remains debated; however, recent studies have shown cyst location is random and behavioural effects are not (1,2). In rodents, Toxoplasma infection causes a reduced fear response to feline odours (3–7). While Toxoplasma infection in humans used to be considered transitory, it is now clear there are long-lasting effects of infection. In humans, Toxoplasma infection is positively correlated with the development of schizophrenia and Alzheimer’s disease (8–11). It is known that other protozoans make functional exosomes as reported in the literature for Plasmodium falciparum, Trichomonas sp. and Leishmania (12–14). It has also been reported that Toxoplasma-infected cells make proinflammatory exosomes that increase Tumour necrosis factor-α (TNF-α) production. However, there was no further characterization of those extracellular vesicles (15). It is also known that viral infection causes a cell to change the protein content of the exosomes it secretes (16). Therefore, we hypothesize that Toxoplasma and/or toxoplasma-infected cells produce exosomes that could be a contributing factor to pathology and perhaps behavioural changes in secondary hosts. Exosomes, a sub-population of extracellular vesicles, are small vesicles formed in the endosomal pathway and loaded with various RNAs and proteins. Exosomes are released from the parent cells constitutively, with increases in times of cellular stress. They are then internalized by or bind to neighbouring cells where they release their contents. The contents of the exosomes then exert effects on the recipient cell based on the species of RNA and protein contained in the exosome.

Since the mechanism of Toxoplasma infection associated behavioural pathology is yet to be elucidated, and other protozoa produce exosomes, we hypothesized that exosomes from Toxoplasma or host cells produce exosomes that play a role in pathogenesis. To investigate our hypothesis, we examined supernatants of infected HFF and found extracellular vesicles of the correct size for exosomes that we called exosome-like vesicles (ELVs) by electron microscopy. Furthermore, when we explored the RNA contents using microarrays, we found human mRNA content to be unique when compared to ELVs from uninfected cells.

**Methods**

**Cell culture and Toxoplasma infection**

Human foreskin fibroblasts (HFF) were grown to confluence in tissue culture DMEM 10% foetal bovine serum (FBS) and infected with approximately 2.0 MOI, multiplicity of infection, of fresh Prugniaud strain of *Toxoplasma gondii* or deprived of FBS. Serum starvation was used as a way to induce exosome production from the HFF at the time points analyzed, as normal levels of exosome production in unstressed HFF did not yield enough RNA for our study. Serum starvation ultimately induces apoptosis but is known to increase the production of extracellular vesicles as well (17). After an incubation period of 24- or 72-hours, the supernatant was collected from the cultures. Each experiment consisted of 20 T-75 flasks per condition that were pooled for vesicles isolation. We conducted 3 experiments at the 72-hour time period and 1 at the 24-hour time period.

**Extracellular vesicle isolation**

Extracellular vesicles were isolated by a method outlined in Lässer et al. 2012 (18). In brief, supernatants were harvested from SS and Toxo groups and centrifuged at 300 × g for 10 minutes at 4°C. The supernatant was transferred to new centrifuge tubes where it was centrifuged at 16,500 × g for 20 minutes at 4°C. The supernatant was then transferred to ultra-centrifuge tubes and centrifuged at 140,000 × g for 45 minutes at 4°C. The pellet containing extracellular vesicles was resuspended in 200 μl PBS. A sample was sent for electron microscopy to determine the presence and size of extracellular vesicles.

**RNA isolation**

The ELVs-samples were treated with 1,000 U RNase and DNase for 20 minutes at 37°C. After nuclease treatment, RNA was purified from the ELVs utilizing the Trizol® RNA purification method as per manufacturer’s recommendations. RNA was quantified utilizing UV spectrophotometry.

**RT-PCR**

Purified RNA was used to create Template DNA with Invitrogen’s First-Strand cDNA Synthesis Kit with Superscript III Reverse Transcriptase® and oligo (dt) as per manufacturer’s protocol.

**Microarray procedure**

Purified RNA from whole cell lysates, ELVs from Toxoplasma-infected HFF, and ELVs from serum-starved (SS) HFF uninfected with Toxoplasma were submitted for microarray analysis to the University of Pennsylvania Microarray core facility as per their protocols (19). We used the Affymetrix human gene 1.0 st mRNA chip, covering a RefSeq (Entrez) gene count of 21,014 genes, to identify mRNA species in the RNA isolated from our exosome preparations. For microRNA analysis, the Affymetrix microRNA Genechip with Genisphere FlashTag® was used. For Toxoplasma gene product analysis, a proprietary University of Pennsylvania microarray core Toxoplasma expression chip was used. Data analysis providing differential expression values was performed by the University of Pennsylvania’s
microarray facility utilizing GeneSpring® software. Expression data for mRNA were confirmed by use of RT-PCR amplification of specific mRNA of interest.

**Electron microscopy**

Samples were placed as a drop on to Parafilm. Formvar/carbon-coated nickel grids (Ted Pella Inc., Redding, USA), which had been pre-UV-treated for 5 minutes were placed on top of the drop. The samples were fixed in 2% paraformaldehyde and washed with PBS. Next, the samples were immunostained with anti-CD63 antibody (BD Bioscience, Erembodegem, Belgium) or isotype control (Sigma-Aldrich, St. Louis, MO, USA), followed by staining with a 10 nm gold-labelled secondary antibody (Sigma-Aldrich). The samples were then fixed in 2.5% glutaraldehyde, washed in ddH₂O and contrasted in 2% uranyl acetate. The preparations were examined in a LEO 912AB Omega electron microscope (Carl Zeiss NTS, Jena, Germany).

**Results**

Electron microscopy revealed extracellular vesicles in the preparations from Toxoplasma-infected HFF (Toxo) and SS HFF, being the correct size of exosomes (≈100 nm), but no CD63 was detected (Fig. 1). We believe they are, in fact, exosomes, but we are calling them ELVs until they are further characterized. As our methodology was novel in utilizing microarray analysis of contents of ELVs to examine the effects of Toxoplasma infection on cell culture, it is important to note observations made from initial analysis of the microarray data included as acceptable microarray RNA quality control data (Supplementary File). Furthermore, we observed unique expression profiles for mRNA and miRNA data for ELVs from Toxo HFF compared to ELVs from SS HFF, which differed greatly from samples of ELVs not treated with nuclease and those from whole cell lysates, indicating our methodology of extracellular vesicle purification, RNA isolation and utilization of microarray analysis was successful (Supplementary File). While our methodology was successful and merited further analysis of the mRNA and miRNA data, not all of our data were easily interpreted. We did not see evidence of Toxoplasma RNA in ELVs, but we do not know if that is due to low levels of Toxo gene expression relative to humans or whether they are included at all (Supplementary File). Upon further analysis of the raw comparative human mRNA expression data (Supplementary File), a strategy was developed for picking salient genes from the multitude of those uniquely represented in the ELVs from Toxo compared to SS. First, we ranked the expression of Toxo/SS in descending order revealing 222 mRNA at the 24-hour time point that were more than 5-fold greater in Toxo ELVs compared to SS ELVs. We then screened out RNA with descriptions indicating they were of ribosomal, mitochondrial and microRNA origin, leaving a manageable list of genes that are highly represented in Toxo ELVs compared to SS ELVs. We chose the 11 highest represented mRNA at the 72-hour time point to further investigate (Table I).

Interestingly, our microarray analysis also highlighted the potential presence of ribosomes in the preparation of our ELVs. It is known that the centrifugal method of ELVs isolation has these issues. We do not feel that this negatively impacts the findings we report today. However, the presence of ribosomes will need to be addressed before investigating function and mechanism of the ELVs. Also of note, it appears that the contents of ELVs are not just a representation of the transcriptome of the cell, as the mRNA species representation ratios, comparing Toxo to SS cells, in ELVs are different from the same comparison using the transcriptome of the whole cell. For example, for ELVs harvested 24 hours post-infection, Metallothionein 2A is represented at 47.49-fold greater concentration in Toxo ELVs than SS ELVs, while whole cell expression of the same gene is only

![Fig. 1. Electron microscopy of vesicle preparations. SS and Toxo vesicle-enriched samples were negative stained and revealed extracellular vesicles of approximately 80–90 nm, the correct dimensions for exosomes.](http://dx.doi.org/10.3402/jev.v2i0.22484)
0.89-fold (Table I). This suggests that Toxoplasma infection and Serum Starvation results in production of unique ELVs and is not just mirroring cell transcription. It is known that Toxoplasma infection has a great influence on cellular transcription (34/36), but this is the first description of the production of specific ELVs contents. It is interesting to note that several of the selected highly represented mRNA in ELVs from Toxoplasma-infected cells have been described in the literature as having neurologic roles. Eukaryotic translation elongation factor 1 alpha 1-autism association, Thymosin beta 4 provides neuroprotection following traumatic brain injury, LLP-homolog reported to promote synapse development, and Rab-13 promotes neurite growth and development (23,26,30/33,37). Of the mRNA chosen for closer analysis, several had notable differences between the 24- and 72-hour time point. For example, SET nuclear oncogene, RNA, U1 small nuclear 1 and thymosin beta 4, X-linked (TMSB4X) were all highly represented in the 72-hour time point and less at the 24-hour time point. Also, LLP homolog was more highly represented at the 24-hour time point than at the 72-hour time point.

PCR was used to confirm several representative mRNA (Fig. 2). A strong signal was detected within the Toxo ELVs and little to no signal in the SS ELVs for all mRNA primer pairs that produced any signal, including MTH2A, SEC61G, SET Oncogene, TMSB4X and Rab-13. This data strongly confirmed the microarray findings.

To ensure that full-length mRNA transcript was present in the ELVs and not just fragmented RNA, we performed PCR for the full length Rab13 mRNA. Primers for full length Rab13 mRNA were chosen from NCBI Reference Sequence: NM_002870.2 spanning the mRNA sequence from base pair 111 to 1,086, giving an expected PCR product size of 975 bp. While the PCR reaction was not perfectly clean, showing a smear of smaller products, a distinct band of the expected size was clearly visible just below the 1,000 bp marker (Fig. 3), indicating the presence of full length mRNA in Toxo ELVs.

For miRNA detection, we used the Affymetrix microRNA Genechip® with Genisphere FlashTag®. Because of the high homology of miRNA, the chip returned positive expression data in multiple species. We restricted our analysis to human miRNA on the chip (Raw data available in Supplementary File). The high interspecies homology

### Table I. mRNA expression in ELVs comparing vesicular mRNA at 24- and 72-hours versus whole cell lysate expression.

| mRNA                               | ELVs fold-expression Toxo/SS | Whole cell fold-expression Toxo/SS | Identified function                                                                 |
|------------------------------------|------------------------------|-----------------------------------|-----------------------------------------------------------------------------------|
| Metallothionein 2A (MT2A)          | 130.5                        | 47.5                              | Frequently observed in invasive human breast cancer (20).                          |
| Ferritin, heavy polypeptide 1 (FTH1) | 87.0                        | 38.1                              | Iron binding (21).                                                                |
| Eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) | 67.6                        | 18.5                              | Multiple functions: role in apoptosis inhibition and linked to autism (22,23).      |
| Protein transport protein Sec61 subunit gamma (Sec61G) | 53.2                        | 21.2                              | A subunit of the protein translocation channel at the endoplasmic reticulum (24). |
| Rab13 (RAS member)                | 88.6                        | 28.5                              | Multiple functions: neuronal regeneration and actin cytoskeletal rearrangements (25,26). |
| SET nuclear oncogene (SET)        | 34.7                         | 9.0                               | Proto-oncogene (27,28).                                                          |
| Zinc finger protein 253 (ZNF253)  | 40.3                         | 29.8                              | Unknown: Assumed DNA binding                                                     |
| RNA, U1 small nuclear 1           | 33.1                         | 2.7                               | Multiple functionality                                                            |
| Thymosin beta 4, X-linked (TMSB4X)| 24.7                         | 4.4                               | Multiple functions: actin sequestration and neuroprotection following traumatic brain injury protection (29–31). |
| H2A histone family, member Z (H2AFZ) | 26.3                        | 11.0                              | Histone protein subunit                                                          |
| LLP homolog (LLPH)                | 5.1                          | 17.8                              | Long-term synaptic facilitation (Aplysia) (32,33).                                 |

Values are reported as fold-expression Toxo/SS.
raises the possibility of bovine serum ELVs contamination, which was not an issue with the human mRNA data. Generally, the enrichment of specific species of miRNA in ELVs was less than that seen in the mRNA data with the greatest difference being 10.8-fold for miRNA compared to 130.5-fold for mRNA. Furthermore, compared to whole cell lysates (Toxo/SS), the contents of ELVs (Toxo/SS) are enriched and not a reflection of cytoplasmic miRNA levels (Table II). A general trend is difficult to ascertain from the miRNA data, because the individual miRNA has been associated with seemingly opposing functions. For example, miR-125b has been reported to cause apoptosis of cancer cells on the one hand and confer a chemoresistant profile on the other (38–40). However, many of the miRNA species detected regulate cell proliferation and are associated with a variety of cancers, including miR-92a, miR-125b, miR-125a-5p, miR-503 and miR-99a-star. Interestingly, one of the most enriched species of miRNA, miR-23b, which is enriched 10.8-fold at the 24-hour time point in Toxo ELVs, plays an anti-inflammatory role causing the down regulation of IL-17 production and response (41).

**Discussion**

The data we present are important because they show that a new mechanism for Toxoplasma pathogenesis is possible. ELVs from infected cells could attach and deliver their contents to uninfected cells, thereby causing the function of uninfected cells to be altered by the addition of the vesicle contents. It is clear from RT-PCR...
that full-length transcripts of mRNA are present, protected inside of ELVs even after strong nuclease treatment. Full-length mRNA transcripts of neurologically active proteins we report here could alter brain chemistry to the point of behavioural changes. This proposed mechanism would make the exact location of the infected cells less important, as the effect would be spread by the secretion of ELVs from infected cells throughout the brain. If this mechanism is experimentally proven, Toxoplasma could join the ranks of protozoan pathogens that manipulate the host using exosomes, such as *Trichomonas vaginalis* that produces exosomes that deliver their contents to host cells and modulate host cell immune responses and the parasite’s adherence to host cells (13); *Leishmania* sp. producing its own exosomes that influence macrophages to secrete Interleukin-8, necessary to promote infection (14); and *Plasmodium falciparum* which has recently been shown to produce extracellular vesicles to exchange genetic material such as drug resistance genes (12). However, unlike the above listed Protozoans, Toxoplasma does not appear to be releasing ELVs containing its own genetic material.

Here, we have shown that ELVs are produced by Toxoplasma-infected cell ELVs are distinct from RNA from ELVs produced by SS cells. Indeed, the mRNA microarray data from 24- and 72-hour post-infection time points produced similar results, but not identical, providing further support for the validity of the method and experimental findings. Among the most highly represented mRNA in ELVs from Toxoplasma-infected cells were 4 mRNA for proteins that have been previously reported to have neurologic activity: Eukaryotic translation elongation factor 1 alpha 1, Thymosin beta 4, LPP-homolog and Rab-13. Perhaps adding to the importance of the data is the fact that these ELVs were created by fibroblasts and not neurons, which might be expected to more readily produce significant amounts of neurologically relevant mRNA.

Expression data for miRNA is more difficult to interpret without direct physical experimentation to determine the specific effects, due to many miRNA species having seemingly opposite expression profiles in similar pathologic states: miR-125b reported to cause apoptosis of cancer cells on one hand and conferred a chemoresistant profile to cancer cells on the other (38-40). However, the role of one miRNA seems resolute. miR-23b is an anti-inflammatory mediator that suppresses IL-17 production and response. While it may be intended to ameliorate immune-mediated pathology, RNA from Toxoplasma-infected cell ELVs are distinct from RNA from ELVs produced by SS cells. Indeed, the mRNA microarray data from 24- and 72-hour post-infection time points produced similar results, but not identical, providing further support for the validity of the method and experimental findings. Among the most highly represented mRNA in ELVs from Toxoplasma-infected cells were 4 mRNA for proteins that have been previously reported to have neurologic activity: Eukaryotic translation elongation factor 1 alpha 1, Thymosin beta 4, LPP-homolog and Rab-13. Perhaps adding to the importance of the data is the fact that these ELVs were created by fibroblasts and not neurons, which might be expected to more readily produce significant amounts of neurologically relevant mRNA.

Expression data for miRNA is more difficult to interpret without direct physical experimentation to determine the specific effects, due to many miRNA species having seemingly opposite expression profiles in similar pathologic states: miR-125b reported to cause apoptosis of cancer cells on one hand and conferred a chemoresistant profile to cancer cells on the other (38-40). However, the role of one miRNA seems resolute. miR-23b is an anti-inflammatory mediator that suppresses IL-17 production and response. While it may be intended to ameliorate immune-mediated pathology,
suppression of the inflammatory IL-17 response is also likely to aid in the infection process, which would be a similar function reported for Leishmania sp. (14).

The exact impact ELVs from Toxoplasma-infected cells may have on the pathogenesis of Toxoplasma cannot be certain without direct experimentation. However, these data certainly raise the possibility that neurologic effects of Toxoplasma may be, in part, impacted by production of RNA-laden ELVs we described here. It becomes attractive to conjecture that the Toxoplasma parasite could be exerting influence over the exact content of ELVs to promote its own survival. However, much more study needs to be done before such a conclusion could be made. Indeed, little is known about many of the fundamental mechanisms of ELVs production. Among the fundamental questions that beckon for further study are: How is the production of ELVs regulated? How is RNA loaded into ELVs? How does the cell specify which RNA is loaded? Our future studies will focus on these fundamental aspects of ELVs production.

Acknowledgements

Special thanks to Jan Lotval, MD, PhD, for gracious collaboration and to Daniel Beiting, PhD, for invaluable technical support and for supplying the HFF and Prugniaud strain of Toxoplasma gondii stocks. Kentucky College of Osteopathic Medicine was the sole provider of funding for these studies. Thanks to Garred R. Cline OMSIV for assistance in the laboratory.

Conflict of interest and funding

Authors have no conflicts of interest to declare. Experiments needed to do before such a conclusion could be made. Indeed, little is known about many of the fundamental mechanisms of ELVs production. Among the fundamental questions that beckon for further study are: How is the production of ELVs regulated? How is RNA loaded into ELVs? How does the cell specify which RNA is loaded? Our future studies will focus on these fundamental aspects of ELVs production.

References

1. Berenreiterova M, Flegr J, Kubena AA, Nemec P. The distribution of Toxoplasma gondii cysts in the brain of a mouse with latent toxoplasmosis: implications for the behavioral manipulation hypothesis. PLoS One. 2011;6:e28925.
2. Di Cristina M, Marocco D, Galizi R, Proietti C, Spaccapelo R, Crisanti A. Temporal and spatial distribution of Toxoplasma gondii differentiation into Bradyzoites and tissue cyst formation in vivo. Infect Immun. 2008;76:3491–501.
3. Kannan G, Moldovan K, Xiao J-C, Yolken RH, Jones-Brando L, Pletnikov MV. Toxoplasma gondii strain-dependent effects on mouse behaviour. Folia Parasitol. 2010;57:151–5.
4. da Silva RC, Langoni H. Toxoplasma gondii: host–parasite interaction and behavior manipulation. Parasitol Res. 2009;105:893–8.
5. Webster JP. The effect of Toxoplasma gondii on animal behavior: playing cat and mouse. Schizophr Bull. 2007;33:752–6.
6. Vyas A, Kim S-K, Giacomini N, Boothroyd JC, Sapolsky RM. Behavioral changes induced by Toxoplasma infection of rodents are highly specific to aversion of cat odors. Proc Natl Acad Sci U S A. 2007;104:6442–7.
7. Vyas A, Kim SK, Sapolsky RM. The effects of toxoplasma infection on rodent behavior are dependent on dose of the stimulus. Neuroscience. 2007;148:342–8.
8. Flegr J. Influence of latent Toxoplasma infection on human personality, physiology and morphology: pros and cons of the Toxoplasma-human model in studying the manipulation hypothesis. J Exp Biol. 2013;216:127–33.
9. Arias I, Sorolzano A, Villegas E, de Dios Luna J, McKenney K, Cervilla J, et al. Infectious agents associated with schizophrenia: a meta-analysis. Schizophr Res. 2012;136:128–36.
10. Torrey EF, Bartko JJ, Lun ZR, Yolken RH. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr Bull. 2007;33:729–36.
11. El-Sahn AA, Shatat HZ, Ghiyani EM. Seropositivity of toxoplasmosis in patients with schizophrenia. J Egypt Public Health Assoc. 2005;80:509–24.
12. Regev-Rudzki N, Wilson Danny W, Carvalho Teresa G, Sisquella X, Coleman Bradley M, Rug M, et al. Cell–Cell Communication between Malaria-Infected Red Blood Cells via Exosome-like Vesicles. Cell. 2013;153:1120–33.
13. Wu O, de Miguel N, Lustig G, Stevens GC, Vashisht AA, Wohlschlegel JA, et al. Trichomonas vaginalis exosomes deliver Cargo to host cells and mediate Hostriato Parasite interactions. PLoS Pathog. 2013;9:e1003482.
14. Silverman JM, Clos J, de’Oliveira CC, Shirvani O, Yang F, Wang C, et al. An exosome-based secretion pathway is responsible for protein export from Leishmania and communication with macrophages. J Cell Sci. 2010;123:842–52.
15. Bhatnagar S, Shinagawa K, Castellino FJ, Schoey JS. Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. Blood. 2007;110:3234–44.
16. Meckes DG Jr., Gunawardena HP, Dekroon RM, Heaton PR, Edwards RH, Ozgur S, et al. Modulation of B-cell exosome proteins by gamma herpesvirus infection. Proc Natl Acad Sci U S A. 2013;110(31):E2925–33.
17. Sirosi I, Raymond MA, Brassard N, Cailhier JF, Fedjaev M, Hanelin K, et al. Caspase-3-dependent export of TCTP: a novel pathway for antiapoptotic intercellular communication. Cell Death Differ. 2011;18:549–62.
18. Lässer C, Ekdahl M, Lotvall J. Isolation and characterization of RNA-containing exosomes. J Vis Exp. 2012;(59):e3037. doi: 10.3791/3037.
19. Searce LM, Brestelli JE, McWeeney SK, Lee CS, Mazzarelli J, Pinney DF, et al. Functional genomics of the endocrine pancreas: the pancreas clone set and PanCChip, new resources for diabetes research. Diabetes. 2002;51:1997–2004.
20. Jin R, Chow VT, Tan PH, Dheen ST, Duan W, Bay BH. Metallothionein 1A expression is associated with cell proliferation in breast cancer. Carcinogenesis. 2002;23:81–6.
21. Laghaei R, Evans DG, Coalson RD. Metal binding sites of human H-chain ferritin and iron transport mechanism to the ferroxidase sites: a molecular dynamics simulation study. Proteins. 2013;81:1042–50.
22. Blanch A, Robinson F, Watson IR, Cheng LS, Irwin MS. Eukaryotic translation elongation factor 1-alpha 1 inhibits p53 and p73 dependent apoptosis and chemotherapy sensitivity. PLoS One. 2013;8:E66436.
23. Tsai NP, Wilkerson JR, Guo W, Maksimova MA, DeMartinio GN, Cowan CW, et al. Multiple autism-linked genes mediate synapse elimination via proteasomal degradation of a synaptic scaffold PSD-95. Cell. 2012;151:1581–94.
24. Kelkar A, Dobberstein B. Sec61beta, a subunit of the Sec61 protein translocation channel at the endoplasmic reticulum, is involved in the transport of Gurken to the plasma membrane. BMC Cell Biol. 2009;10:11.
25. Sakane A, Abdallah AA, Nakano K, Honda K, Ikeda W, Nishikawa Y, et al. Rab13 small G protein and junctional Rab13-binding protein (JRAB) orchestrate actin cytoskeletal
organization during epithelial junctional development. J Biol Chem. 2012;287:42455–68.
26. Sakane A, Honda K, Sasaki T. Rab13 regulates neurite outgrowth in PC12 cells through its effector protein, JRA/ MICAL-L2. Mol Cell Biol. 2010;30:1077–87.
27. Adachi Y, Pavlakis GN, Copeland TD. Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. J Biol Chem. 1994;269:2258–62.
28. Lam BD, Anthony EC, Hordijk PL. Cytoplasmic targeting of the proto-oncogene SET promotes cell spreading and migration. FEBS Lett. 2013;587:111–9.
29. Jeon BJ, Yang Y, Kyung Shim S, Yang HM, Cho D, Ik Bang S. Thymosin beta-4 promotes mesenchymal stem cell proliferation via an interleukin-8-dependent mechanism. Exp Cell Res. 2013;319:2526–34.
30. Xiong Y, Zhang Y, Mahmood A, Meng Y, Zhang ZG, Morris DC, et al. Neuroprotective and neurorestorative effects of thymosin beta-4 treatment initiated 6 hours after traumatic brain injury in rats. J Neurosurg. 2012;116:1081–92.
31. Xiong Y, Mahmood A, Meng Y, Zhang Y, Zhang ZG, Morris DC, et al. Neuroprotective and neurorestorative effects of thymosin beta-4 treatment following experimental traumatic brain injury. Ann N Y Acad Sci. 2012;1270:51–8.
32. Eckel-Mahan KL, Storm DR. Rooke snail protein LAPS veteran C/EBP: net transcriptional proceeds for long-term facilitation. Neuron. 2006;49:645–6.
33. Kim H, Chang DJ, Lee JA, Lee YS, Kaang BK. Identification of nuclear/nucleolar localization signal in Aplysia learning associated protein of slug with a molecular mass of 18 kDa homologous protein. Neurosci Lett. 2003;343:134–8.
34. Ong YC, Boyle JP, Boothroyd JC. Strain-dependent host transcriptional responses to Toxoplasma infection are largely conserved in mammalian and avian hosts. PLoS One. 2011;6:e26369.
35. Zeiner GM, Norman KL, Thomson JM, Hammond SM, Boothroyd JC. Toxoplasma gondii infection specifically induces miRNA and messenger RNA expression of human thymosin beta4 treatment following experimental traumatic brain injury. Ann N Y Acad Sci. 2012;1270:51–8.
36. Chaussabel D, Semnani RT, McDowell MA, Sacks D, Sher A, Zeiner GM, Norman KL, Thomson JM, Hammond SM, Kappelmann M, Kuphal S, Meister G, Vardimon L, Bosserhoff AK. MicroRNA mir-125b controls melanoma progression by direct regulation of c-Jun protein expression. Oncogene. 2013;32:2984–91.
37. Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res. 2011;17:2725–33.
38. Jiang L, Huang Q, Chang J, Wang E, Qu X. MicroRNA HSA-miR-125a-5p induces apoptosis by activating p35 in lung cancer cells. Exp Lung Res. 2011;37:89–98.
39. Zhao B, Ma R, Si W, Li S, Xu Y, Tu X, et al. MicroRNA-203 targets FGFR2 and VEGF and inhibits xenograft growth. Cancer Lett. 2013;333:159–69.
40. Yan Q, Li W, Tang Q, Yao S, Lv Z, Feng N, et al. Cellular microRNAs 498 and 320d regulate herpes simplex virus 1 induction of Kaposi’s sarcoma-associated herpes virus lytic replication by targeting TRA. PLoS One. 2013;8:e55832.
41. Sun D, Lee YS, Malhotra A, Kim HK, Matesic M, Evans C, et al. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res. 2011;71:1313–24.
42. Li D, Liu X, Lin L, Hou J, Li N, Wang C, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem. 2011;286:36677–85.

*Saman M. Pope
Department of Biomedical Sciences
Marian University College of Osteopathic Medicine
3200 Cold Spring Road
Indianapolis, IN 46222
USA
Tel: +317 955 6275
Email: spope@marian.edu

Citation: Journal of Extracellular Vesicles 2013, 2: 22484 - http://dx.doi.org/10.3402/jev.v2i0.22484